Notable Downgrades: Valeant Pharma (VRX), Arista Networks (ANET), Calpine (CPN), Jumei (JMEI)

Analysts at Goldman (GS) downgraded Valeant Pharmaceuticals International, Inc. (VRX) from ‘Buy’ to ‘Neutral’ in a research report issued to clients on Monday. The name was also lowered to $172 from $224 at Jefferies. Separately, today S&P lowered corporate credit rating on Valeant to ‘B+’ from ‘BB-‘/rating outlook is “negative”. On valuation measures, Valeant Pharmaceuticals […] View the full post at: Notable Downgrades: Valeant Pharma (VRX), Arista Networks (ANET), Calpine (CPN), Jumei (JMEI) Related posts: Pre-Market Earnings (May 3) Pharma Megamergers: Will They Continue? Moody’s Downgrades Japan Triple-As Currency Credit Rating